AEON Biopharma, Inc. (AEON) stock forecast & analysis
0.2425
NYSE American · USD
Down: -0.0038, -1.5%
0.2423Down: -0.0002, -0.1%
2 analyses
- Open
- 0.2540
- Previous close
- 0.2463
- Day range
- 0.2400 – 0.2668
- 52-week range
- 0.1770 – 1.45
- Volume (shares)
- 2.08M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 49.88M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.65
- Market cap
- 12.10M
Market Scanner’s AI analysis of AEON Biopharma, Inc. (AEON), updated September 2026: AEON Biopharma's ABP-450 comparability to BOTOX® and recent financing efforts were central to recent analyses, alongside ongoing net losses.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of AEON Biopharma, Inc. (AEON) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
AEON Biopharma's ABP-450 comparability to BOTOX® and recent financing efforts were central to recent analyses, alongside ongoing net losses.
Recent analyses for AEON Biopharma covered the company's pilot forced degradation results for ABP-450, highlighting its analytical comparability to BOTOX®. Developments included participation in a growth conference, a public offering, and a regulatory appointment. The company's financial performance was characterized by significant net and operating losses in recent annual and quarterly reports.
AEON news & sentiment
News reports highlighted AEON Biopharma's pilot forced degradation results for ABP-450 and its comparability to BOTOX®, alongside corporate actions like a public offering and a regulatory appointment. Social media discussion was not covered in the provided notes.
AEON technical picture
AEON's price action showed a recent upward movement after a significant decline, with momentum readings mixed between short-term positive and longer-term bearish trends. The stock traded below key moving averages, while indicators suggested strong buying pressure alongside neutral momentum and bearish divergence.
Fundamentals
AEON Biopharma has reported significant net and operating losses in recent annual and quarterly periods. The company's market capitalization and stock price have fluctuated, trading below its 50-day and 200-day moving averages.
Factors discussed — upside
- Positive pilot forced degradation results for ABP-450 showing analytical comparability to BOTOX®
- Expanded structural data showing molecular similarity to BOTOX®
- Regained compliance with NYSE American continued listing standards
- Priced an underwritten public offering of approximately $13.8 million
- Money Flow Index (MFI) in overbought territory indicating strong buying pressure
Factors discussed — risks
- Significant net losses in recent years and quarters
- Significant operating losses in recent years and quarters
- Stock price trading below both 50-day and 200-day SMAs
- 91-day price change shows a significant decline
- Biopharmaceutical research
- Financial performance
- Market trends
- Corporate actions
Summary updated .
AEON technical indicators
Common technical indicators for AEON, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.27 | Price below |
| 10-day exponential moving average | 0.26 | Price below |
| Relative strength index (14-day) | 43.61 | Neutral |
| MACD line (12/26/9) | -0.0102 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.19 – 0.33 | Price inside the bands |
Analyses
Recent AEON.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for AEON Biopharma, Inc.?
- The bull case for AEON Biopharma centers on positive pilot forced degradation results for ABP-450, indicating analytical comparability to BOTOX®, alongside expanded structural data showing molecular similarity. The company has also regained compliance with NYSE American listing standards and successfully priced a public offering.
- What are the risks for AEON Biopharma, Inc.?
- Risks for AEON Biopharma include significant net and operating losses reported in recent annual and quarterly periods. The stock price is currently trading below its 50-day and 200-day simple moving averages, and the 91-day price change indicates a substantial decline.
- Is AEON Biopharma, Inc. bullish or bearish?
- Recent AI analyses of AEON Biopharma, Inc. examined factors on both sides. Discussed upside: The bull case for AEON Biopharma centers on positive pilot forced degradation results for ABP-450, indicating analytical comparability to BOTOX®, alongside expanded structural data showing molecular similarity. The company has also regained compliance with NYSE American listing standards and successfully priced a public offering. Discussed risks: Risks for AEON Biopharma include significant net and operating losses reported in recent annual and quarterly periods. The stock price is currently trading below its 50-day and 200-day simple moving averages, and the 91-day price change indicates a substantial decline. These are descriptive observations, not a recommendation.
- What is the latest sentiment on AEON Biopharma, Inc.?
- News reports highlighted AEON Biopharma's pilot forced degradation results for ABP-450 and its comparability to BOTOX®, alongside corporate actions like a public offering and a regulatory appointment. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse AEON Biopharma, Inc.?
- Every analysis of AEON Biopharma, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh AEON.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every AEON.US report already in the library